A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel

International Agency for Research on Cancer. Prostate cancer: estimated incidence, mortality, and prevalence worldwide. GLOBOCAN Web site. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx (20 March 2014, date last accessed). Walczak, 2007, Prostate cancer: a practical approach to current management of recurrent disease, Mayo Clin Proc, 82, 243, 10.1016/S0025-6196(11)61005-7 Chi, 2009, Castration-resistant prostate cancer: from new pathophysiology to new treatment targets, Eur Urol, 56, 594, 10.1016/j.eururo.2009.06.027 Beer, 2014, Enzalutamide in metastatic prostate cancer before chemotherapy, N Engl J Med, 371, 424, 10.1056/NEJMoa1405095 de Bono, 2010, Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial, Lancet, 376, 1147, 10.1016/S0140-6736(10)61389-X de Bono, 2011, Abiraterone and increased survival in metastatic prostate cancer, N Engl J Med, 364, 1995, 10.1056/NEJMoa1014618 Fizazi, 2012, Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study, Lancet Oncol, 13, 983, 10.1016/S1470-2045(12)70379-0 Kantoff, 2010, Sipuleucel-T immunotherapy for castration-resistant prostate cancer, N Engl J Med, 363, 411, 10.1056/NEJMoa1001294 Parker, 2013, Alpha emitter radium-223 and survival in metastatic prostate cancer, N Engl J Med, 369, 213, 10.1056/NEJMoa1213755 Rathkopf, 2014, Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302), Eur Urol, 66, 815, 10.1016/j.eururo.2014.02.056 Ryan, 2013, Abiraterone in metastatic prostate cancer without previous chemotherapy, N Engl J Med, 368, 138, 10.1056/NEJMoa1209096 Ryan, 2015, Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castraton-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomized, double-blind, placebo-controlled, phase 3 study, Lancet Oncol, 16, 152, 10.1016/S1470-2045(14)71205-7 Scher, 2012, Increased survival with enzalutamide in prostate cancer after chemotherapy, N Engl J Med, 367, 1187, 10.1056/NEJMoa1207506 Tannock, 2004, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer, N Engl J Med, 351, 1502, 10.1056/NEJMoa040720 Scher, 2005, Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis, J Clin Oncol, 23, 8253, 10.1200/JCO.2005.03.4777 National Comprehensive Cancer Network, 2013 Mallett, 2010, Reporting performance of prognostic models in cancer: a review, BMC Med, 8, 21, 10.1186/1741-7015-8-21 Ryan, 2013, Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial, J Clin Oncol, 31, 2791, 10.1200/JCO.2012.45.4595 Scher, 2015, Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer, J Clin Oncol, 33, 1348, 10.1200/JCO.2014.55.3487 Chen, 1985, The bootstrap and identification of prognostic factors via Cox's proportional hazards regression model, Stat Med, 4, 39, 10.1002/sim.4780040107 Heagerty, 2005, Survival model predictive accuracy and ROC curves, Biometrics, 61, 92, 10.1111/j.0006-341X.2005.030814.x Ravi, 2014, External validation of a prognostic model predicting overall survival in metastatic castrate-resistant prostate cancer patients treated with abiraterone, Eur Urol, 66, 8, 10.1016/j.eururo.2014.03.020 Gillessen, 2015, Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015, Ann Oncol, 26, 1589, 10.1093/annonc/mdv257 1993, A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project, N Engl J Med, 329, 987, 10.1056/NEJM199309303291402 Motzer, 1999, Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma, J Clin Oncol, 17, 2530, 10.1200/JCO.1999.17.8.2530 Heng, 2009, Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study, J Clin Oncol, 27, 5794, 10.1200/JCO.2008.21.4809 Zhou, 2014, An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era, Blood, 123, 837, 10.1182/blood-2013-09-524108 Armstrong, 2010, Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer, Clin Cancer Res, 16, 203, 10.1158/1078-0432.CCR-09-2514 Halabi, 2010, The importance of identifying and validating prognostic factors in oncology, Semin Oncol, 37, e9, 10.1053/j.seminoncol.2010.04.001 Halabi, 2014, Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer, J Clin Oncol, 32, 671, 10.1200/JCO.2013.52.3696 Fizazi, 2015, Bone-related parameters are the main prognostic factors for overall survival in men with bone metastases from castration-resistant prostate cancer, Eur Urol, 68, 42, 10.1016/j.eururo.2014.10.001 Smaletz, 2002, Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration, J Clin Oncol, 20, 3972, 10.1200/JCO.2002.11.021 Berry, 1979, Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate, Cancer, 44, 763, 10.1002/1097-0142(197908)44:2<763::AID-CNCR2820440251>3.0.CO;2-5 Halabi, 2003, Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer, J Clin Oncol, 21, 1232, 10.1200/JCO.2003.06.100